Literature analysis of adverse reactions induced by olaparib
10.12173/j.issn.1005-0698.202411077
- VernacularTitle:奥拉帕利所致不良反应病例文献分析
- Author:
Jialing WANG
1
;
Dong ZOU
Author Information
1. 宁波市第六医院药学部(浙江 宁波 315040)
- Publication Type:Journal Article
- Keywords:
Olaparib;
Adverse drug reactions;
Case report;
Literature analysis
- From:
Chinese Journal of Pharmacoepidemiology
2025;34(3):324-332
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the occurrence regularities and clinical characteristics of the adverse reactions induced by olaparib,and provide a reference for rational drug use in clinical practice.Methods The case reports and case analyses of the adverse reactions induced by olaparib were retrieved from databases of CNKI,Wanfang Data,VIP,PubMed,Web of Science,Embase,and conduct statistical analysis on the basic information of patients,the use of drugs,the induction time of adverse reactions,clinical manifestations,treatment,and outcomes.Results A total of 20 case reports of adverse reactions to olaparib were collected,involving 23 patients and 25 adverse reactions,including 6 males and 17 females.The majority of patients were over 50 years old(20 cases,86.96%),with an average age of(61.60±9.52)years.The main underlying disease was ovarian cancer(14 cases,60.87%).The occurrence time of adverse reactions is relatively evenly distributed in different periods,with a higher probability of occurring within 180 days(20 cases,80.00%).Adverse reactions mainly involved the blood system(28.00%),respiratory system(24.00%),and skin system(24.00%).Three patients recovered after discontinuing the medication,two patients recovered after reducing the dosage,and 11 patients recovered after discontinuing the medication and receiving symptomatic treatment.One patient died after discontinuing medication and receiving symptomatic treatment,while four patients died before discontinuing medication.Two patients did not mention any improvement.Conclusion Adverse reactions related to olaparib should be highly valued,and medication monitoring should be strengthened to reduce or stop administration promptly after adverse reactions occur,to reduce the risks of clinical medication.
